Opening a New Lipid "Apo-thecary": Incorporating Apohpoprotezns as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk

August 2011
Mayo Clinic Proceedings;Aug2011, Vol. 86 Issue 8, p762
Academic Journal
Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) represent the cornerstone of drug therapy to reduce low-density lipoprotein (LDL) cholesterol and cardiovascular risk. However, even optimal statin management of LDL cholesterol leaves many patients with residual cardiovascular risk, in part because statins are more effective In reducing LDL cholesterol than apolipoprotein B (Apo B). Apo B may be a better marker of atherogenic risk than LDL cholesterol because Apo B measures the total number of all atherogenic particles (total atherosclerotic burden), including LDL, very low-density lipoprotein, intermediate-density lipoprotein, remnant lipoproteins, and lipoprotein(a). To determine whether Apo B Is a better Indicator of baseline cardiovascular risk and residual risk after lipid therapy compared with LDL cholesterol, a MEDLINE search of the literature published in English from January 1, 1975, through December 1, 2010, was conducted. On the basis of data from most population studies, elevated Apo B was more strongly associated with Incident coronary heart disease than similarly elevated LDL cholesterol. Apo B was also a superior benchmark (vs LDL cholesterol) of statins' cardioprotective efficacy in both primary-prevention and secondary-prevention trials. To minimize cardiovascular risk among persons with hypercholesterolemia or dysilpidemia, the best available evidence suggests that intensive therapy with statins should be initiated to achieve the lowest possible Apo B level (with adequate drug toleration) and then other therapies (eg, niacin, bile acid resins, ezetimibe) added to potentiate these Apo B-lowering effects. In future consensus lipid-lowering treatment guidelines, Apo B should be considered as an index of residual risk, a potential parameter of treatment efficacy, and a treatment target to minimize risk of coronary heart disease.


Related Articles

  • Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin. Derosa, Giuseppe; Maffioli, Pamela // Clinical Medicine Reviews in Therapeutics;2011, Vol. 3, p311 

    The progression of atherosclerosis and thus risk of cardiovascular disease is influenced by a variety of risk factors, including high levels of low-density lipoprotein cholesterol (LDL-C) and low levels of high-density lipoprotein cholesterol (HDL-C). Lowering the serum cholesterol level with...

  • Emerging Therapies and Their Role in Comprehensive Lipid Management. Vinall, Maria // MD Conference Express;Oct2011, p6 

    The article focuses on the clinical trials which aimed to evaluate low-density lipoprotein cholesterol (LDL-C) targets and assess their significance on treatment approaches. It mentions the result of the PROVE-IT trial which support intensive statin therapy after acute coronary syndrome (ACS),...

  • Statin Therapy in Very Elderly Patients with CAD. Miller, Karl E. // American Family Physician;3/15/2003, Vol. 67 Issue 6, p1354 

    Discusses the study 'Statin Therapy Is Associated With Reduced Mortality Across All Age Groups of Individuals With Significant Coronary Disease, Including Very Elderly Patients,' by C.A. Maycock et al., from the November 20, 2002 issue of the 'Journal of American College Cardiology.'

  • New Cholesterol Guidelines Establish A Lower LDL Level For Those At Highest Risk.  // RN;Aug2004, Vol. 67 Issue 8, p18 

    Presents an update to national practice guidelines for treating patients with high cholesterol. Setting up a lower goal for low-density lipoprotein cholesterol levels; Consideration of a drug therapy sooner among certain groups of high-risk patients; Review of major clinical trials of statin...

  • Dyslipidemia in Obesity: Mechanisms and Potential Targets. Klop, Boudewijn; Elte, Jan Willem F.; Cabezas, Manuel Castro // Nutrients;Apr2013, Vol. 5 Issue 4, p1218 

    Obesity has become a major worldwide health problem. In every single country in the world, the incidence of obesity is rising continuously and therefore, the associated morbidity, mortality and both medical and economical costs are expected to increase as well. The majority of these...

  • Coronary Risk Factors in the Elderly: Their Interactions and Treatment. Carbonin, Pierugo; Zuccal�, Giuseppe; Marzetti, Emanuele; Lo Monaco, Maria Rita // Current Pharmaceutical Design;Nov2003, Vol. 9 Issue 29, p2465 

    Coronary disease is currently a major cause of disability and mortality in older populations. Due to several factors - including increased noncardiovascular mortality, atypical presentation of coronary events, selective survival, and, possibly, clustering of protective genetic traits - the...

  • Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease. Hu, M.; Mak, V. W. L.; Chu, T. T. W.; Waye, M. M. Y.; Tomlinson, B. // Current Pharmacogenomics & Personalized Medicine;2009, Vol. 7 Issue 1, p1 

    The statins are the most important group of drugs for lipid-lowering therapy in the prevention of coronary heart disease. Greater reductions in LDL-cholesterol appear to be associated with greater benefits but the clinical efficacy and safety of statin treatment varies considerably from person...

  • Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial K channels and ROS signalling. Perrelli, Maria-Giulia; Tullio, Francesca; Angotti, Carmelina; Cerra, Maria; Angelone, Tommaso; Tota, Bruno; Alloatti, Giuseppe; Penna, Claudia; Pagliaro, Pasquale // Pflugers Archiv European Journal of Physiology;Jul2013, Vol. 465 Issue 7, p1031 

    Catestatin (CST) limits myocardial ischaemia/reperfusion (I/R) injury with unknown mechanisms. Clearly phosphoinositide-3-kinase (PI3K), protein kinase C (PKC) isoforms, including intra-mitochondrial PKCε, mitochondrial K (mitoK) channels and subsequent reactive oxygen species...

  • A new framework for reverse cholesterol transport: Non-biliary contributions to reverse cholesterol transport. Temel, Ryan E.; Mark Brown, J. // Annals of Gastroenterology & Hepatology;2011, Vol. 9 Issue 93, p5946 

    Reduction of low-density lipoprotein-cholesterol through statin therapy has only modestly decreased coronary heart disease (CHD)-associated mortality in developed countries, which has prompted the search for alternative therapeutic strategies for CHD. Major efforts are now focused on therapies...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics